CA2657291A1 - Symbiotic maple product compositions and methods - Google Patents
Symbiotic maple product compositions and methods Download PDFInfo
- Publication number
- CA2657291A1 CA2657291A1 CA2657291A CA2657291A CA2657291A1 CA 2657291 A1 CA2657291 A1 CA 2657291A1 CA 2657291 A CA2657291 A CA 2657291A CA 2657291 A CA2657291 A CA 2657291A CA 2657291 A1 CA2657291 A1 CA 2657291A1
- Authority
- CA
- Canada
- Prior art keywords
- maple
- sap
- probiotics
- probiotic
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000208140 Acer Species 0.000 title abstract description 145
- 239000000203 mixture Substances 0.000 title abstract description 55
- 238000000034 method Methods 0.000 title abstract description 20
- 239000006041 probiotic Substances 0.000 abstract description 96
- 235000018291 probiotics Nutrition 0.000 abstract description 96
- 235000013406 prebiotics Nutrition 0.000 abstract description 61
- 235000008504 concentrate Nutrition 0.000 abstract description 32
- 239000012141 concentrate Substances 0.000 abstract description 32
- 235000020357 syrup Nutrition 0.000 abstract description 30
- 239000006188 syrup Substances 0.000 abstract description 30
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000000529 probiotic effect Effects 0.000 description 48
- 239000000047 product Substances 0.000 description 45
- 229920001202 Inulin Polymers 0.000 description 28
- 229940029339 inulin Drugs 0.000 description 28
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 27
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 20
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 19
- 230000002496 gastric effect Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 9
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 9
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 9
- 230000007407 health benefit Effects 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 229940009289 bifidobacterium lactis Drugs 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- -1 (e) a pentosan Polymers 0.000 description 3
- 229920000189 Arabinogalactan Polymers 0.000 description 3
- 239000001904 Arabinogalactan Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000019312 arabinogalactan Nutrition 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960004903 invert sugar Drugs 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 235000005340 Asparagus officinalis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 2
- 240000008892 Helianthus tuberosus Species 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MLNKXLRYCLKJSS-RMKNXTFCSA-N (2e)-2-hydroxyimino-1-phenylethanone Chemical compound O\N=C\C(=O)C1=CC=CC=C1 MLNKXLRYCLKJSS-RMKNXTFCSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 240000002767 Acer grandidentatum Species 0.000 description 1
- 235000010319 Acer grandidentatum Nutrition 0.000 description 1
- 235000010328 Acer nigrum Nutrition 0.000 description 1
- 235000002629 Acer saccharinum Nutrition 0.000 description 1
- 235000010157 Acer saccharum subsp saccharum Nutrition 0.000 description 1
- 235000018645 Allium odorum Nutrition 0.000 description 1
- 244000003377 Allium tuberosum Species 0.000 description 1
- 235000005338 Allium tuberosum Nutrition 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 241001134654 Lactobacillus leichmannii Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000438617 Schedorhinotermes intermedius Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- JYTUFVYWTIKZGR-UHFFFAOYSA-N holmium oxide Inorganic materials [O][Ho]O[Ho][O] JYTUFVYWTIKZGR-UHFFFAOYSA-N 0.000 description 1
- OWCYYNSBGXMRQN-UHFFFAOYSA-N holmium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Ho+3].[Ho+3] OWCYYNSBGXMRQN-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000019823 konjac gum Nutrition 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000012069 sugar maple Nutrition 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to novel maple product compositions. In particular, the present invention relates to new compositions comprising maple sap, maple concentrate or maple syrup and probiotics, prebiotics or combinations thereof. The present invention also discloses methods for the production products, including functional drinks, comprising a composition comprising maple sap, maple concentrate or maple syrup and probiotics, prebiotics or combinations thereof, as a vehicle for the delivery of probiotics and prebiotics to the gastrointestinal tract.
Description
SYMBIOTIC MAPLE PRODUCT COMPOSITIONS AND METHODS
FIELD OF THE INVENTION
[0001] The present invention relates to novel maple product compositions. In particular, the present invention relates to new compositions comprising maple sap, maple concentrate or maple syrup and probiotics, prebiotics or combinations thereof, and to methods for the production and stabilisation of a functional drink comprising a composition comprising maple sap, maple concentrate or maple syrup and probiotics, prebiotics or combinations thereof, as a vehicle for the delivery of probiotics and prebiotics to the gastrointestinal tract.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
[0001] The present invention relates to novel maple product compositions. In particular, the present invention relates to new compositions comprising maple sap, maple concentrate or maple syrup and probiotics, prebiotics or combinations thereof, and to methods for the production and stabilisation of a functional drink comprising a composition comprising maple sap, maple concentrate or maple syrup and probiotics, prebiotics or combinations thereof, as a vehicle for the delivery of probiotics and prebiotics to the gastrointestinal tract.
BACKGROUND OF THE INVENTION
[0002] There are a number of health drinks in the market containing probiotics and/or prebiotics. Virtually all major brands of commercial milk products have at least one milk product enriched with probiotics and/or prebiotics such as Danone DanActiveTM, Astro Biobest Maximmunit6TM and Natrel ProTM.
[0003] Natural spring waters and fruit juices are sold in pure form or flavoured with some enrichment minerals and/or vitamins. However, none are enriched with probiotics and/or prebiotics, mainly because the chemical composition of the water source does not support this type of enrichment.
[0004] The neutral pH of milk, its fat and protein content are the elements that provide a protective effect and allow the probiotic action in the gastro-intestinal system. The acidity of fruit juice does not allow for the inoculation and the survival of probiotics.
[0005] It is known that maple sap is a source of naturally distilled, pure water. It is also known in the art that the water found in sap may be removed, for example, during the production of maple syrup in order to market and sell the water as non-carbonated, "pure and natural distilled and condensed Maple Steam" (for example, available as VERMONT MAPLE
WATERTM from Vermont Maple Water, Inc., East Arlington, Vt. 05252).
WATERTM from Vermont Maple Water, Inc., East Arlington, Vt. 05252).
[0006] Canadian patent application No. 2,594,937 ('937 application) discloses the use of maple sap as a medium in a bioreactor to grow probiotics under continuous agitation at 37 C and 3152340.1 in the presence of a substrate rich in nitrogen, such as soy drink. The `937 application does not suggest or teach the use of pure, non-supplemented sap, maple concentrate or maple syrup in a composition as a delivery vehicle for probiotics, prebiotics or a combination thereof.
[0007] Using maple sap, maple concentrate or maple syrup in a functional drink as a delivery vehicle for probiotics and/or prebiotics present a number challenges that are not solved by the prior art, namely: (1) to ensure the survival of probiotic strains inoculated in the sap, maple concentrate or maple syrup; (2) to select commercial probiotic strains that are resistant to environment; (3) to inoculate sufficient quantity of probiotic strains in the composition to maintain a good survival rate and maintain the organoleptic characteristics and the environment;
(4) to produce a product with a reasonable shelf-life and (5) to maintain a good survival rate of probiotics in the gastrointestinal (stomach and small intestine) system of the subject ingesting the symbiotic composition. Several factors in the gastrointestinal system such as bile salts, enzymes, pH and temperature decrease and even go so far as to inhibit the action of probiotics. It is an object of this invention to overcome these challenges.
(4) to produce a product with a reasonable shelf-life and (5) to maintain a good survival rate of probiotics in the gastrointestinal (stomach and small intestine) system of the subject ingesting the symbiotic composition. Several factors in the gastrointestinal system such as bile salts, enzymes, pH and temperature decrease and even go so far as to inhibit the action of probiotics. It is an object of this invention to overcome these challenges.
[0008] It is an object of the present invention to provide a drink that provides health benefits. Until the invention presented herein, the enrichment of maple sap or maple concentrate with prebiotics and probiotics was never implemented.
BRIEF SUMMARY OF THE INVENTION
BRIEF SUMMARY OF THE INVENTION
[0009] A novel composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof has now been developed, which is useful as a health composition.
[0010] Thus, in one aspect of the present invention a composition suitable to be delivered to a mammalian gut, comprising maple sap, maple concentrate or maple syrup and at least one probiotic is provided.
[0011] In another aspect of the present invention a composition suitable to be delivered to a mammalian gut, comprising maple sap, maple concentrate or maple syrup and at least one prebiotic is provided.
3152340.1
3152340.1
[0012] In yet another aspect of the present invention a composition suitable to be delivered to a mammalian gut, comprising maple sap, maple concentrate or maple syrup, at least one probiotic and at least one prebiotic is provided.
[0013] In still another aspect of the present invention, a functional drink comprising a composition suitable to be delivered to a mammalian gut, said composition comprising maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof is provided.
[0014] In one aspect a method of producing a composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof, is provided.
[0015] In another aspect a method of using a composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof, is provided.
[0016] Advantages of the compositions of the present invention include:
[0017] (1) The ability to provide a symbiotic drink with no calories, that is refreshing, hydrating and with added health benefits.
[0018] (2) Probiotics and prebiotics provided in a single product (which is not always the case).
[0019] (3) The ability to provide probiotic-containing product with a life shelf-life of up to 30 days when kept at 4 C.
[0020] (4) The ability to maintain a good survival rate of probiotics in the gastrointestinal system.
[0021] These and still other objects and advantages of the present invention will be apparent from the description which follows.
3152340.1 BRIEF DESCRIPTION OF THE DRAWINGS
3152340.1 BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The present invention will become more fully understood from the detailed description given herein and from the accompanying drawings, which are given by way of illustration only and do not limit the intended scope of the invention.
[0023] Figure 1 is an illustration of the storage survival rate of L.
rhamnosus and B. lactis Bb12 in maple sap, with or without added 2% inulin, at 4 C for 30 days.
rhamnosus and B. lactis Bb12 in maple sap, with or without added 2% inulin, at 4 C for 30 days.
[0024] Figure 2 is a graph showing the viability of B. lactis in gastrointestinal multicompartmental dynamic model (TIM-1) during digestion of maple sap sample without added inulin.
[0025] Figure 3 is a graph showing the viability of L. rhamnosus in gastrointestinal multicompartmental dynamic model (TIM-1) during digestion of maple sap sample without added inulin.
[0026] Figure 4 is a graph showing the viability of B. lactis in gastrointestinal multicompartmental dynamic model (TIM-1) during digestion of maple sap sample with added 2% (w/v) inulin.
[0027] Figure 5 is a graph showing the viability of L. rhamnosus in gastrointestinal multicompartmental dynamic model (TIM-1) during digestion of maple sap sample with added 2% (w/v) inulin.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[0028] A novel composition is provided. In one aspect, the composition of the present invention comprises a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof. In another aspect the present invention provides for a. method of producing a composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof.
In yet another aspect, the present invention provides for a method of using a composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof.
3152340.1
In yet another aspect, the present invention provides for a method of using a composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof.
3152340.1
[0029] The compositions of the present invention can be used to produce improved beverages, foods, and feeds, and other products for increasing levels of healthful bacteria and/or prebiotics in mammalian guts.
[0030] For the purpose of this application, the following terms have the following meanings:
[0031] "Probiotic" is defined by the United Nations Food and Agricultural Organization and the World Health Organization as "live microorganisms, which, when administered in adequate amounts, confer a health benefit on the host". "Prebiotic" means any substance that acts as a substrate to any relevant probiotic, or that otherwise assists in keeping the relevant probiotic alive or stimulates its growth, and includes mucopolysaccharides, oligosaccharides, polysaccharides, amino acids, vitamins, nutrient precursors and proteins. The association of probiotics with prebiotics gives rise to compositions/products generally defined by the term "symbiotic".
[0032] Maple sap is a naturally occurring, unprocessed crystal-clear liquid, having the consistency and clarity of water, which derives from the sugar maple tree.
Maple sap has sugar content that is anywhere from approximately 1 to 5 Brix. The sugar content in sap depends on the harvest period, temperature, exposure to sun, the maple region, size and age of the maple.
The har vest of sap is made in the spring, between March and April, when the temperature is below the freezing point during the night and greater than zero degrees Celsius during the day.
The majority of the sugar content in maple sap comprises sucrose and glucose.
The remainder of the maple sap content (95-98%) consists of naturally occurring water and very small amounts of organic acids, a portion of which is responsible for the maple flavor. The nitrogen content in sap is 0.25% in the form of organic nitrogen from amino acids and proteins. The sugars are sources of carbon that may be greatly appreciated by the probiotic strains.
Arabinogalactan was also identified in the Maple Products (Desjardins, Y. 2007. Caracterisation de produits d'erable lyophilises.In. Quebec: INAF/Universite Laval. 94 pages). Arabinogalactan is a polysaccharide widely used as prebiotic to stimulate the growth of probiotics in the gastrointestinal tract.
According to the same publication, other products were also found as organic acids, vitamins, minerals, flavonoids and phenolic compounds. The pH of maple sap ranges from 6.5 to 7 with a tendency to decrease towards the end of the sugaring season. Microbial contamination of the sap 3152340.1 is mainly composed of Pseudomonas type varies from 102 to 106 increasing to the end of the season. Maple syrup is the viscous liquid obtained by concentration and heat treatment of maple sap.
Maple sap has sugar content that is anywhere from approximately 1 to 5 Brix. The sugar content in sap depends on the harvest period, temperature, exposure to sun, the maple region, size and age of the maple.
The har vest of sap is made in the spring, between March and April, when the temperature is below the freezing point during the night and greater than zero degrees Celsius during the day.
The majority of the sugar content in maple sap comprises sucrose and glucose.
The remainder of the maple sap content (95-98%) consists of naturally occurring water and very small amounts of organic acids, a portion of which is responsible for the maple flavor. The nitrogen content in sap is 0.25% in the form of organic nitrogen from amino acids and proteins. The sugars are sources of carbon that may be greatly appreciated by the probiotic strains.
Arabinogalactan was also identified in the Maple Products (Desjardins, Y. 2007. Caracterisation de produits d'erable lyophilises.In. Quebec: INAF/Universite Laval. 94 pages). Arabinogalactan is a polysaccharide widely used as prebiotic to stimulate the growth of probiotics in the gastrointestinal tract.
According to the same publication, other products were also found as organic acids, vitamins, minerals, flavonoids and phenolic compounds. The pH of maple sap ranges from 6.5 to 7 with a tendency to decrease towards the end of the sugaring season. Microbial contamination of the sap 3152340.1 is mainly composed of Pseudomonas type varies from 102 to 106 increasing to the end of the season. Maple syrup is the viscous liquid obtained by concentration and heat treatment of maple sap.
[0033] "Maple concentrate" is maple sap concentrated at, for example, 10 Brix having passed through a reverse osmosis membrane which has the effect of concentrating the sugars and nutrients from the maple sap. The concentrated sap may then be routed to produce maple syrup.
[0034] "Maple product" in this document refers to maple sap, maple concentrate or maple syrup, and any product derived from maple sap, maple concentrate or maple syrup.
[0035] As used in this specification and the appended claims, the singular forms "a,"
"an," and "the" include both the singular and the plural unless the context clearly dictates otherwise. For example, a composition containing "a probiotic" includes a composition having one probiotic or two or more probiotics, and "a prebiotic" includes a prebiotic or two or more prebiotics. Each of the terms "includes," "include," "comprises" and "comprise" means "includes at least." For example, "a prebiotic comprising inulin" means the prebiotic includes at least inulin; it may also include other prebiotics and/or other substances.
"an," and "the" include both the singular and the plural unless the context clearly dictates otherwise. For example, a composition containing "a probiotic" includes a composition having one probiotic or two or more probiotics, and "a prebiotic" includes a prebiotic or two or more prebiotics. Each of the terms "includes," "include," "comprises" and "comprise" means "includes at least." For example, "a prebiotic comprising inulin" means the prebiotic includes at least inulin; it may also include other prebiotics and/or other substances.
[0036] The present invention comprises one or more of the following: (a) a novel composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof, (b) a novel drink comprising a composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof and (c) methods of producing and using composition comprising a maple sap, maple concentrate or maple syrup and at least one of a probiotic, a prebiotic or a combination thereof.
[0037] Probiotics that may be used to practice the invention are microorganisms that can survive in maple products and benefit mammalian (particularly human) health, particularly gastrointestinal health. The probiotic that may be used to practice the invention includes one or more of a Lactobacilli and Bifidobacteria. Specific probiotics that may be used include, but are not limited to, one or more of Lactobacillus (abbreviated "L") rhamnosus, L.
acidophilus, L.
plantarum, L. reuteri, L. curvatus, L. bulgaricus, L. grasseri, L. casei, L.
fermentum, L.
caveasicus, L. helveticus, L. lactis, L. salivarius, L. brevis, L. leichmanni, L. cellobiosus, L.
3152340.1 buchneri, Bifidobacterium (abbreviated as "B,") laterosporus, B. lactis Bb12, B. longum, B.
breve, B. subtilus, L. sporogenes (also known as Bacillus coagulans), pediococcus acidilactici, pediococcus pentosaceus, enterococcus faecium, B. adolescentis, B. infantis, B. thermophilum, B. animalis, and B. bifidum. Steptococcus thermphilius may also be used, which is believed to improve lactose digestion and make micronutrients more available to the host.
Other probiotics that may be used include Lactococcus lactis cremoris, S. diacetylactis and S.
intermedius.
acidophilus, L.
plantarum, L. reuteri, L. curvatus, L. bulgaricus, L. grasseri, L. casei, L.
fermentum, L.
caveasicus, L. helveticus, L. lactis, L. salivarius, L. brevis, L. leichmanni, L. cellobiosus, L.
3152340.1 buchneri, Bifidobacterium (abbreviated as "B,") laterosporus, B. lactis Bb12, B. longum, B.
breve, B. subtilus, L. sporogenes (also known as Bacillus coagulans), pediococcus acidilactici, pediococcus pentosaceus, enterococcus faecium, B. adolescentis, B. infantis, B. thermophilum, B. animalis, and B. bifidum. Steptococcus thermphilius may also be used, which is believed to improve lactose digestion and make micronutrients more available to the host.
Other probiotics that may be used include Lactococcus lactis cremoris, S. diacetylactis and S.
intermedius.
[0038] In one aspect of the present invention the probiotic strains that may be used to practice the invention include L. rhamnosus, L. acidophilus, L. plantarum, B.
lactis Bb12 and B.
longum. In another aspect of the present invention the probiotic strains that may be used to practice the present invention include L. rhamnosus and B. lactis Bb12.
lactis Bb12 and B.
longum. In another aspect of the present invention the probiotic strains that may be used to practice the present invention include L. rhamnosus and B. lactis Bb12.
[0039] Commercially available strains of Lactobacilli and Bifidobacteria may be obtained from Chris Hansen (USA).
[0040] The minimum effective dose of probiotics is not precisely known, however, an oral dose of 108 Colony Forming Units (cfu) or more per day may be necessary to achieve health benefits. Enzymes, bile salts, pancreatic secretions, pH, temperature and transit time through the gastrointestinal track will directly affect the survival of probiotics. In general, passage through the digestive system results in 1 log inhibition of probiotics.
[0041] Moreover, the concentration of probiotics in a drink or product will be directly linked to the volume of the drink and product consumed. For example, a 100ml drink inoculated with 1010 cfu probiotics a probiotic concentration of 108 cfu / ml. After ingestion of the drink, there is a loss of about 1 log, and the consumer would have absorbed 107 cfu in probiotics and provide the health benefits expected. A probiotic concentration of at least 108 cfu / ml ensures that the final amount in the digestive system will be 107 cfu.
[0042] Prebiotics that may be used to practice the instant invention comprise one or more of the following (a) an oligosaccharide, (b) a fructo-oligosaccharide ("FOS"), such as a soy fructo-oligosaccharide, inulin or banana fiber, (c) a pectin or pectic polysaccharide, (d) a mannan, such as guar gum, locust bean gum, konjac, or xanthan gum, (e) a pentosan, beta-glucan, arabinan and galactan, such as larch arabinogalactan, (f) serum peptides and (g) mixtures thereof.
3152340.1
3152340.1
[0043] FOS are long-chain polysaccharides comprised primarily of fructose monosaccharides bonded together by 1-0-D-fructofuranosyl linkages. Upon ingestion, fructo-oligosaccharides are only partially hydrolyzed as they pass through the mouth, stomach, and small intestine. In the large intestine, they become food for certain probiotics, such as L.
acidophilus and B. infantis and are metabolized into SCFAS, mainly acetic, propionic, butyric, and lactic acids. As a consequence of this fermentation, a considerable amount of bacterial mass is produced. This results in increased numbers of probiotic, a lowered intestinal pH, and is believed to inhibit pathogens. A pH decrease will increase solubility of calcium and other minerals and may enhance the absorption of calcium and magnesium. Illustrative fructo-oligosaccharides include inulin, banana fiber, and soy fructo-oligosaccharides, and are found in honey, beer, onion, asparagus, Chinese chive, maple sugar, oats, and Jerusalem artichoke.
acidophilus and B. infantis and are metabolized into SCFAS, mainly acetic, propionic, butyric, and lactic acids. As a consequence of this fermentation, a considerable amount of bacterial mass is produced. This results in increased numbers of probiotic, a lowered intestinal pH, and is believed to inhibit pathogens. A pH decrease will increase solubility of calcium and other minerals and may enhance the absorption of calcium and magnesium. Illustrative fructo-oligosaccharides include inulin, banana fiber, and soy fructo-oligosaccharides, and are found in honey, beer, onion, asparagus, Chinese chive, maple sugar, oats, and Jerusalem artichoke.
[0044] Inulin is produced naturally in an estimated 36,000 or more plants worldwide including onion, asparagus, artichoke, and many cereals. Chicory root and Jerusalem artichoke each contain a significant amount of inulin. In addition to encouraging the growth of probiotics, some animal and human studies suggest that inulin oligosaccharides provide the benefit of enhancing calcium and magnesium absorption in the small intestine.
[0045] Some specific prebiotics that may be used to practice the invention include: (1) FOS=; (2) short chain FOS; (3) inulin; (4) resistant starch; (5) starches such as starches derived from natural corn starch, (6) larch arabinogalactan, (7) hydrogenated lactose, and (8) serum proteins.
[0046] In one aspect, the composition according to the instant invention is a symbiotic composition comprising a maple product, a probiotic and a prebiotic. In one aspect the prebiotic complements the probiotic in the symbiotic composition, but the prebiotic may complement another probiotic, such as one present in the intestines but not in the composition.
[0047] The inventors discovered that probiotics inoculated in unsterilised sap and concentrate maple could not survive due to the action of the endogenous flora of the sap and concentrate maple. In order to inoculate the sap, maple concentrate or maple syrup with probiotics and expect a survival of the inoculate over a long period of time, it is essential to inactivate endogenous flora (bacteria in the sap) by a sterilization treatment that does not alter the endogeous nutraceutical compounds (intrinsic qualities) of the sap, maple concentrate or 3152340.1 maple syrup as the endogenous nutraceutical compounds comprise essential nutrients for the survival of the inoculated probiotics. The inventors tested several thermal processes such as extended 55 C/30 minutes at 121 C/15 minutes coupled with a UV or microfiltration. In one aspect of the present invention the sterilization process which reduces the endogenous flora and maintains the intrinsic qualities of the product (sap, concentrated sap of maple or maple syrup) is a sterilization process comprising continuously combining a mild heat treatment (63 C / 20 minutes or 80 C / 10 minutes) followed by a microfiltration step on a nylon membrane (0.8 m).
The sterilization treatment can eliminate the microbial load of treated products including psychotropic, yeasts and molds. On average, endogenous flora reduction of approximately 7 log was obtained and no micro-organism was detected after four months storage at 4 C. The physico-chemical analysis showed that the new sterilization process resulted in only minor changes in terms of product features including a slight decline in total solids and an increase in invert sugar. No changes were observed at the level of pH, which remained stable between 6 and 7 during storage. These minor changes do not affect the integrity of the product, its taste and the survival of probiotics.
The sterilization treatment can eliminate the microbial load of treated products including psychotropic, yeasts and molds. On average, endogenous flora reduction of approximately 7 log was obtained and no micro-organism was detected after four months storage at 4 C. The physico-chemical analysis showed that the new sterilization process resulted in only minor changes in terms of product features including a slight decline in total solids and an increase in invert sugar. No changes were observed at the level of pH, which remained stable between 6 and 7 during storage. These minor changes do not affect the integrity of the product, its taste and the survival of probiotics.
[0048] The sugar content of the maple product may affect the viability of the added probiotics. Thus, in one aspect the present invention is a composition comprising a maple product and at least one of a probiotic or a prebiotic or a combination thereof, wherein the maple product has 10 to 20 Brix. In other aspects the present invention is a composition comprising a maple product and at least one of a probiotic or a prebiotic or a combination thereof, wherein the maple product has 10 to 10 Brix. In other aspects the present invention is a composition comprising a maple product and at least one of a probiotic or a prebiotic or a combination thereof, wherein the maple product has 1 0 to 5 Brix.
[0049] It is desirable to provide compositions comprising maple products and at least one of a probiotic or a prebiotic or a combination thereof having a reasonable shelf-life. Thus, in another aspect of the present invention is a composition comprising a maple product and at least one of a probiotic or a prebiotic or a combination thereof, wherein said composition has a shelf life of at least 30 days at 4 C.
3152340.1
3152340.1
[0050] In other aspects of the present invention, the storage time of the compositions of the invention may be increased by submitting the compositions of the invention to a freezing process.
[0051] In one aspect of the instant invention, a symbiotic composition of the invention would comprise of up to 10i0 cfu/ml probiotic and up to 3% prebiotic. In one aspect, the probiotic and prebiotic represent up to 2% of the composition. The composition may be delivered in combination with any other substance or compound, such as enteral food, as long as the other substance or compound does not destroy the ability of the symbiotic composition to confer a beneficial effect. For example, the composition may comprise prebiotics other than those specifically described herein, such as bifidius factor (currently available only from human milk), minerals, vitamins, phytochemicals, enzymes, lactoperoxidase, thiocyanate salt, lactoferrin, gluconic acid, phytochemical, amino acids and/or other substances that may benefit the probiotic of choice or otherwise benefit the subject.
[0052] The compositions of the present invention may be ingested orally as a drink.
However, the compositions may also be ingested as a tablet or capsule.
However, the compositions may also be ingested as a tablet or capsule.
[0053] Any capsule or tablet suitable for at least partially protecting the probiotic as it passes through the stomach, thus allowing a greater amount of probiotic to enter the large intestine than would enter without use of the capsule or tablet, may be used.
Such a tablet may have a generally homogenous composition or include individual layers containing the various constituents of the tablet (such as the probiotic and prebiotic).
Such a tablet may have a generally homogenous composition or include individual layers containing the various constituents of the tablet (such as the probiotic and prebiotic).
[0054] Having described preferred embodiments of the invention, alterations and modifications within its scope may occur to others. The scope of the invention is not limited to the particular examples, process steps, or materials disclosed as preferred embodiments but is instead set forth in the appended claims and legal equivalents thereof.
Example 1 - Processing of maple sap
Example 1 - Processing of maple sap
[0055] Maple sap, maple concentrate and maple syrup were sterilized by a sterilization process that comprises of continuously combining a mild heat treatment (63 C/20 minutes or 80 C/10 minutes) followed by a microfiltration step on a nylon membrane (0.8 m) followed by a treatment at 63 C for 15 or 30 minutes.
3152340.1
3152340.1
[0056] The sterilization process resulted in an endogenous microbial reduction of approximately 7 log, and no endogenous microorganisms were dectected after four months storage at 4 T. Physico-chemical analysis showed that the developed process resulted in only minor changes in terms of product features including a slight decline in total solids and an increase in invert sugar. No changes were observed in the pH level, which remained stable between 6 and 7 during said storage. These minor changes do not affect the integrity of the product, its taste and the survival of probiotics.
[0057] This process of cold pasteurisation should be applied to the sap or maple concentrate before the inoculation with probiotics and prebiotics.
Example 2 -Maple sap enrichment with probiotics
Example 2 -Maple sap enrichment with probiotics
[0058] Commercial strains of the genus Lactobacillus (L. rhamnosus, L.
acidophilus and L. plantarum) and Bifidobacterium (B. lactis) were tested for their ability to survive in water of maple. These strains were obtained from the company Chris Hansen (USA) and used as freeze-dried. Sap previously sterilized by the process of cold pasteurization (Example 1) was inoculated with probiotic strains (alone or in combination) at different concentrations (107, 108, 109 CFU/ml) with or without added prebiotics.
Example 3 - Maple sap enrichment with prebiotics
acidophilus and L. plantarum) and Bifidobacterium (B. lactis) were tested for their ability to survive in water of maple. These strains were obtained from the company Chris Hansen (USA) and used as freeze-dried. Sap previously sterilized by the process of cold pasteurization (Example 1) was inoculated with probiotic strains (alone or in combination) at different concentrations (107, 108, 109 CFU/ml) with or without added prebiotics.
Example 3 - Maple sap enrichment with prebiotics
[0059] The effect of enrichment with prebiotics was measured to validate their impact on the rate of survival of the probiotics inoculated as provided in Example 2.
Commercial prebiotics tested include arabinogalactan, inulin and serum proteins. The final prebiotic concentrations were 2.5% for serum protein and 2.5% in inulin.
Example 4 - Survival rate of maple products enriched with probiotics with or without added prebiotics
Commercial prebiotics tested include arabinogalactan, inulin and serum proteins. The final prebiotic concentrations were 2.5% for serum protein and 2.5% in inulin.
Example 4 - Survival rate of maple products enriched with probiotics with or without added prebiotics
[0060] Beginning of season and end of season maple products were enriched as per Example 2 and Example 3, stored at 4 C and tested for probiotic survival at 0, 2, 7 14, 21 and 30 days following incubation with probiotics with or without added prebiotic.
Only two probiotics strains were able to survive in water of maple after 30 days at 4 C:
Lactobacillus rhamnosus and Bifidobacterium lactis Bb12. The results presented in Figure 1 relate the accounts of both 3152340.1 microbial probiotic strains that showed the best survival rates in the sap namely Lactobacillus rhamnosus and Bifidobacterium lactis Bbl 2. Figure 1 clearly illustrates that B. Lactis Bb12, although inoculated with a lower initial concentration (4xl07cfu/ml), is able to survive 30 days of storage at 4 C both in the presence or absence of the prebiotic inulin. A
significant loss was observed after 30 days of storage, which is exceptional given the nature of product inoculated (maple sap concentrate to 2 Brix predominantly sugar). L. rhamnosus for its part has demonstrated a lower survival rate with a loss of about 1 log observed at 30 days of incubation.
Despite this loss, the final observed concentration remains relatively high and sufficient to exert beneficial effects in the gastrointestinal tract.
Example 5 - Physico-chemical analysis of maple products enriched with probiotics
Only two probiotics strains were able to survive in water of maple after 30 days at 4 C:
Lactobacillus rhamnosus and Bifidobacterium lactis Bb12. The results presented in Figure 1 relate the accounts of both 3152340.1 microbial probiotic strains that showed the best survival rates in the sap namely Lactobacillus rhamnosus and Bifidobacterium lactis Bbl 2. Figure 1 clearly illustrates that B. Lactis Bb12, although inoculated with a lower initial concentration (4xl07cfu/ml), is able to survive 30 days of storage at 4 C both in the presence or absence of the prebiotic inulin. A
significant loss was observed after 30 days of storage, which is exceptional given the nature of product inoculated (maple sap concentrate to 2 Brix predominantly sugar). L. rhamnosus for its part has demonstrated a lower survival rate with a loss of about 1 log observed at 30 days of incubation.
Despite this loss, the final observed concentration remains relatively high and sufficient to exert beneficial effects in the gastrointestinal tract.
Example 5 - Physico-chemical analysis of maple products enriched with probiotics
[0061] Analyses were performed to measure the impact of the enrichment of maple products with probiotics on the physico-chemical and organoleptic intrinsic character of the product. The analysis conducted included the determination of pH (pH meter Accumet), total solids (transmission at 560 nm using Beckman 96157 Holmium oxide filter spectrophotometer, refractometer Reichert AR200), invert sugar content (Ascensia Contour Glucometer) and the Maillard reaction (spectrophotometer Beckman 96157).
[0062] No changes were observed in the total solid content after enrichment with probiotics (2.3% for the sap and 10% for the concentrated maple).
[0063] Analysis of pH in the sap revealed values close to neutrality (7) for the sap at the beginning and end of the season both in the presence or absence of probiotics.
[0064] Furthermore, an organoleptic analysis was performed on samples that had an acceptable microbiological quality. In general, the enrichment of the maple products with both selected probiotic strains (L. rhamnosus and B. lactis Bb 12) has not led to significant changes in the organoleptic and sensory characteristics of products.
[0065] The tests performed to study the p hysico-chemical, organoleptic and sensory analyses of maple products co-enriched with prebiotics were the same as those presented previously.
3152340.1
3152340.1
[0066] Higher concentrations (between 4.1 and 6% for the sap and concentrate maple respectively) were detected in samples containing symbiotic inulin, serum protein or mixture of both. This increase is simply due to the enrichment of samples by these prebiotic substances. No change was observed in the total solid content during the 30 days of the study
[0067] Enrichment of the sap with inulin at a concentration of 2% was accompanied by a significant decrease in the pH (4) compared to pH near neutral (7) of sap with or without probiotics.
[0068] In addition, the sap prebiotic enrichment led to disappearance of the maple taste in the sap. To remedy this problem, commercial flavors of maple syrup to maximum concentration of 2% in the finished product, were used. The addition of these flavors made it possible to reproduce a characteristic taste of the sap without affecting the survival of probiotic strains added.
[0069] It may also be desirable to add a natural or artificial flavoring ingredient to the maple sap prior to the pasteurization step to provide a complementary flavor to the product. Fruit flavors have been found to be particularly advantageous for complementing the maple product and may include any one or combination of orange, apple, grapefruit, pineapple, strawberry, raspberry, cranberry, lime, lemon, grape, or peach, or any other suitable flavor, such as vanilla or chocolate that will enhance the refreshing quality of the beverage. Generally these ingredients will be added to the maple sap product in a flavoring amount, i.e., an amount that will not overpower the natural taste and flavor of the maple sap, which will generally be less than about 1% by volume of the final product.
Example 6 - Effectiveness and protective Effect of the symbiotic drink: In vitro study
Example 6 - Effectiveness and protective Effect of the symbiotic drink: In vitro study
[0070] Gastrointestinal dynamic simulator (TIM-1 model)
[0071] The dynamic gastrointestinal TIM-1 model (TNO Nutrition and Food Research Institute, Zeist, Netherlands) was previously described by Minekus et al.
(1995). The Model consists of four compartments simulating the stomach, duodenum, jejunum and ileum, which are connected by computer controlled peristaltic valve pumps. Each compartment is composed of two glass jackets, in which a flexible membrane is installed. The space between the membrane and the glass jacket is filled with warm water which helps to rise temperature of the chyme in 3152340.1 each compartment to 37 C. The contractions of the flexible membranes are achieved by changing the pressure of the water. These contractions allows for imitating the peristaltic movements of the stomach and small intestine and thus mixing the chyme in each compartment.
The contractions frequencies per minute are 5 and 6 times for gastric and duodenal compartments, respectively and 7 times/minute for jejunal and illeal compartments. During digestion, temperature is kept constantly at 37 C and monitored by two independent sensors connected to the stomach and small intestine compartments. To imitate kidney function, two hallow fiber modules are connected to jejunal and illeal compartments. These modules allow for dialyzing the content of each compartment against small intestine electrolyte solution. The pHs in the gastric and small intestine compartments are monitored with four independent pH
electrodes connected to the computer. Secretion of HCl in the gastric compartment or sodium bicarbonate in the small intestine compartments to control pH in various compartments is completely controlled and dosed via the computer.
(1995). The Model consists of four compartments simulating the stomach, duodenum, jejunum and ileum, which are connected by computer controlled peristaltic valve pumps. Each compartment is composed of two glass jackets, in which a flexible membrane is installed. The space between the membrane and the glass jacket is filled with warm water which helps to rise temperature of the chyme in 3152340.1 each compartment to 37 C. The contractions of the flexible membranes are achieved by changing the pressure of the water. These contractions allows for imitating the peristaltic movements of the stomach and small intestine and thus mixing the chyme in each compartment.
The contractions frequencies per minute are 5 and 6 times for gastric and duodenal compartments, respectively and 7 times/minute for jejunal and illeal compartments. During digestion, temperature is kept constantly at 37 C and monitored by two independent sensors connected to the stomach and small intestine compartments. To imitate kidney function, two hallow fiber modules are connected to jejunal and illeal compartments. These modules allow for dialyzing the content of each compartment against small intestine electrolyte solution. The pHs in the gastric and small intestine compartments are monitored with four independent pH
electrodes connected to the computer. Secretion of HCl in the gastric compartment or sodium bicarbonate in the small intestine compartments to control pH in various compartments is completely controlled and dosed via the computer.
[0072] Maple Sap Sample Preparation
[0073] Filtered pasteurized (as provided in Example 1) maple sap samples with or without added 2% inulin (as provided in Example 3) were inoculated with approximately 107-108 cfu/ml of each of Lactobacillus rhamnosus and Bifidobacterium lactis (as provided in Example 2). Briefly, 300 g of the inoculated maple sap sample were then introduced into the stomach compartment of the TIM-1 model.
[0074] Sampling
[0075] During the first two hours of digestion, aliquots of 1 ml from the gastric compartment were taken at 0, 20, 40, 60 and 80 min to evaluate the impact of gastric environment on the viability of Lactobacillus and Bifidobacterium. Aliquots of 1 ml from duodenal compartment (at 30, 60, 90, 120 and 180 min) and from jejunal and illeal compartments (at 60, 120, 180, 240 and 300 min) were also taken for the same purpose. For the determination of illeal-delivered Lactobacillus rhamnosus and Bifidobacterium lactis, briefly 1 ml of illeal-delivered efflux was taken at 1 h intervals for microbiological analyses.
[0076] Microbiological analyses 3152340.1
[0077] Serial 10-fold dilutions of each sample were made in peptone water (0.15%, w/v) and plated in duplicate onto Beerens agar and incubated an aerobically in jars using an atmosphere generation system (Oxoid AnaeroGenTM, Oxoid Ltd., Basingstoke, Hampshire, England) at 37 C for 48 h for the enumeration of Bifidobacterium lactis. For the enumeration of Lactobacillus rhamnosus, appropriate peptone water dilutions of each sample were plated in duplicate onto MRS-vancomycin agar (containing vancomycin at a concentration of 1 mg/1).
Plates were incubated aerobically at 42 C for 72 h.
Plates were incubated aerobically at 42 C for 72 h.
[0078] Data Interpretation and Conclusion The impact of gastrointestinal environment on the viability of Bifidobacterium lactis and Lactobacillus rhamnosus during in vitro digestion of maple sap samples without or with added 2% inulin is presented in Figures 2-5. The figures clearly illustrate that the viability of each organism is reduced remarkably in the gastric (due to acid secretion) and in the duodenal (due to bile secretion) compartments. However, such remarkable reductions in viability of such organism could not be observed in both jejunal or illeal compartments which may be attributing to acid neutralization and bile dilution that had been taken place in both compartments. On the other hand, Lactobacillus rhamnosus appeared to be more susceptible to bile than Bifidobacterium lactis, especially in maple sap samples without added inulin.
This organism could not be detected in the duodenum compartment (Figure 3). Inulin appeared to remarkably improve the tolerance of such organism to gastrointestinal stresses. Inulin contribution to the survival of L. rhamnosus and B. lactis can also be demonstrated by comparing figures 2 and 4 for Bifidobacterium lactis and 3 and 5 for Lactobacillus rhamnosus. The count of such organisms determined in the ileal efflux was remarkably higher in samples with added inulin (Figures 4 and 5) compared with that without inulin (Figures 2 and 3). Without inulin the microorganisms survived in the TIM-1 at levels around 103 to 104 cfu. These levels of cfu may not be enough to exert health benefit. However, the addition of inulin contributed to the survival of the microorganisms in the TIM-1 to levels close to 107 cfu, levels which are known in the art to exert health benefits. Therefore, this in vitro model suggests that in order to exert health benefits, the addition of inulin appears to be necessary for sap samples inoculated with levels of L. rhamnosus and B. lactis between 107 - 108 cfu. Alternatively, in order to exert health benefits, the sap samples may be inoculated with L. rhamnosus and B. lactis at levels higher than 108 cfu, for example at levels of 109 or above.
3152340.1
This organism could not be detected in the duodenum compartment (Figure 3). Inulin appeared to remarkably improve the tolerance of such organism to gastrointestinal stresses. Inulin contribution to the survival of L. rhamnosus and B. lactis can also be demonstrated by comparing figures 2 and 4 for Bifidobacterium lactis and 3 and 5 for Lactobacillus rhamnosus. The count of such organisms determined in the ileal efflux was remarkably higher in samples with added inulin (Figures 4 and 5) compared with that without inulin (Figures 2 and 3). Without inulin the microorganisms survived in the TIM-1 at levels around 103 to 104 cfu. These levels of cfu may not be enough to exert health benefit. However, the addition of inulin contributed to the survival of the microorganisms in the TIM-1 to levels close to 107 cfu, levels which are known in the art to exert health benefits. Therefore, this in vitro model suggests that in order to exert health benefits, the addition of inulin appears to be necessary for sap samples inoculated with levels of L. rhamnosus and B. lactis between 107 - 108 cfu. Alternatively, in order to exert health benefits, the sap samples may be inoculated with L. rhamnosus and B. lactis at levels higher than 108 cfu, for example at levels of 109 or above.
3152340.1
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2657291A CA2657291A1 (en) | 2009-03-06 | 2009-03-06 | Symbiotic maple product compositions and methods |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2657291A CA2657291A1 (en) | 2009-03-06 | 2009-03-06 | Symbiotic maple product compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2657291A1 true CA2657291A1 (en) | 2010-09-06 |
Family
ID=42729275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2657291A Abandoned CA2657291A1 (en) | 2009-03-06 | 2009-03-06 | Symbiotic maple product compositions and methods |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2657291A1 (en) |
-
2009
- 2009-03-06 CA CA2657291A patent/CA2657291A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8551543B2 (en) | Symbiotic maple product compositions and methods | |
Soccol et al. | The potential of probiotics: a review. | |
Prado et al. | Trends in non-dairy probiotic beverages | |
CN1802101B (en) | Use of isomalt (mixture of 1,6 GPS and 1,1 GPM) as a prebiotic for the production of a medicament used for the treatment of intestinal diseases, among other things | |
Khalf et al. | Viability of probiotic bacteria in maple sap products under storage and gastrointestinal conditions | |
US20080299255A1 (en) | Juice beverages with probiotic bacteria | |
Koh et al. | Optimization of a fermented pumpkin-based beverage to improve Lactobacillus mali survival and α-glucosidase inhibitory activity: A response surface methodology approach | |
WO2006039768A1 (en) | Fermented functional food on the basis of soy containing probiotics and prebiotics and process of production thereof | |
CN102665737A (en) | Bifidobacterium longum ATCC BAA-999 (BL999) and weight control | |
PT1150577E (en) | Improved microbial preparations | |
Pimentel et al. | Fruit juices as probiotic foods | |
JP2010512145A (en) | Composition | |
CN105852118A (en) | Anti-reflux infant nutrition | |
Pimentel et al. | Health benefits and technological effects of Lacticaseibacillus casei-01: An overview of the scientific literature | |
Şanlıbaba | Fermented nondairy functional foods based on probiotics | |
Sip et al. | Probiotics and prebiotics | |
Phromthep et al. | Survivability of immobilized Lactobacillus plantarum cells within bacterial cellulose in mamao juice. | |
CA2657291A1 (en) | Symbiotic maple product compositions and methods | |
Nauth | Yogurt | |
Behare et al. | Prebiotic and probiotic food formulations | |
Elshaghabee | Probiotics in Dairy Foods: Advantages and Disadvantages | |
Mountzouris | Nutritional strategies targeting the beneficial modulation of the intestinal microflora with relevance to food safety: The role of probiotics and prebiotics | |
Prakash | Medical Advantages of Fermented Sugarcane Juice with Probiotics on Gut Health | |
Minj et al. | 10 Beneficial Effects of Dairy | |
Subhashree | Development of plant base probiotic nutritional supplement to enhance gut probiotic microflora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |